Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Glioblastoma (GBM) is one of the most aggressive and lethal solid tumors in human. While
efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in
immune activation against abnormal cells. Different from events required for T cell activation …

Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective
responses in adults with glioblastoma, but the feasibility and tolerability of this approach is …

Natural killer (NK) cells are unique innate immune cells and manifest rapid and potent
cytotoxicity for cancer immunotherapy and pathogen removal without the requirement of …

As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has
received increasing attention in recent years, and its safety and high efficiency have …